BRÈVE

sur SANOFI-AVENTIS (EPA:SAN)

Phase III study: Sarclisa improves progression-free survival of patients with multiple myeloma

Sanofi announces promising results for its monoclonal antibody Sarclisa (isatuximab) in combination with a VRd protocol (bortezomib, lenalidomide and dexamethasone). In the Phase III IMROZ study, this treatment reduced the risk of disease progression or death by 40% in patients with newly diagnosed multiple myeloma who were not eligible for transplantation.

At the data cut-off date, the results show a median progression-free survival not reached for Sarclisa-VRd compared to 54.3 months for VRd alone. Additionally, progression-free survival at 60 months was 63.2% for the Sarclisa-VRd group, compared to 45.2% for the VRd group.

Grade ≥3 adverse events affected 91.6% of patients on Sarclisa-VRd and 84% on VRd. No new security signals have been detected. These results are published in the NEJM and presented at ASCO.

R. E.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de SANOFI-AVENTIS